aprott/iStock via Getty Images
The European Medicines Agency announced on Friday that its safety committee has concluded that Novo Nordisk’s (NVO) (OTCPK:NONOF) popular weight loss/diabetes therapy semaglutide can cause a side effect known as non-arteritic anterior ischemic optic neuropathy (NAION) in very rare
